4basebio Plc, a developer of large-scale manufacture of synthetic DNA, has made two senior appointments as the company transitions from an R&D-driven organisation to a rapidly growing commercial one. Scott Lorimer was appointed chief operating officer and Christine Wolosin chief commercial officer. The executives will work closely with Amy Walker, who was appointed as chief executive officer in February 2026, in an accelerated growth strategy. Mr Lorimer brings 30 years’ experience, leading bioprocess development and good manufacturing practice operations in biotechs and CDMOs, including at Instil Bio, Catalent, Sanofi Genzyme and Patheon. Ms Wolosin has been promoted from vice president, business development since joining 4basebio in September 2025. She has 25 years’ experience in life sciences and was vice president of business development at Emmes before joining 4basebio. The company also strengthened its commercial team by promoting James Vang to vice president, business development for his work on commercial expansion and Jennifer Gelman to vice president, marketing, for establishing the company’s market presence and brand positioning.
4basebio announced the appointments on 3 and 12 March 2026.
Copyright 2026 Evernow Publishing Ltd.